Cabaletta Bio, Inc. (CABA)

$ 11.6
+0.34 (+3.02%)
-
Symbol CABA
Price $ 11.6
Beta 1.335
Volume Avg. 0.19M
Market Cap 0.329B
Shares () -
52 Week Range 7.0-16.38
1y Target Est -
DCF Unlevered CABA DCF ->
DCF Levered CABA LDCF ->
ROE -38.73% Strong Sell
ROA -34.01% Strong Sell
Operating Margin -
Debt / Equity 5.16% Neutral
P/E -
P/B 2.14 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CABA news


Dr. Steven Nichtberger
Healthcare
Biotechnology
Nasdaq Global Select

Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. The company is headquartered in Philadelphia, Pennsylvania and currently employs 19 full-time employees. The firm is focused on discovery and development of engineered T-cell therapies for B cell-mediated autoimmune diseases. The T cells are designed to selectively bind and eliminate B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. The Company’s lead CAAR T cell product candidate are designed based on chimeric antigen receptor, and its T cell technology has been developed and is marketed for the treatment of B cell cancers. The firm has discovered and developed four product candidates, including its lead product candidate, to potentially treat patients with mucosal pemphigus vulgaris (mPV), and three additional product candidates that have demonstrated specific and selective target engagement in vitro. Its product pipelines include DSG3-CAART, DSG3/1-CAART, Musk-CAART and FVIII-CAART.